Skip to main content
Premium Trial:

Request an Annual Quote

AbD, e2v Collaborating on Protein Biomarker Point-of-Care System

NEW YORK (GenomeWeb News) – MorphoSys subsidiary AbD Serotec said today that it is collaborating with e2v Biosensors to develop a new protein-quantification system for point-of-care and near-patient testing.
The agreement builds on an initial project that the companies began in 2006 to use AbD’s HuCAL GOLD recombinant antibody technology with e2v’s Visucare single-antibody immunoassay technology.
AbD said it has since generated a series of recombinant antibodies that e2v could use to perform feasibility studies for the Visucare technology.
The e2v technology is based on surface enhanced resonance Raman spectroscopy, or SERRS, an electromagnetic surface-sensitive technique that can detect single molecules binding to a silver surface.
The Visucare platform comprises a HuCAL-based antibody, a reporter SERRS dye linked to peptide, and a silver surface supporting the electromagnetic field. The antibody is immobilized on a silver surface and the SERRS dye peptide is bound to the HuCAL antibody and held outside the electromagnetic field. In the presence of a protein biomarker, the SERRS dye peptide is displaced, binds to the silver surface within the electromagnetic field, and gives off a signal.
According to e2v, Visucare does not need an antibody pair to detect a biomarker, which eliminates the washing and incubation steps that are necessary with other systems and also enables the detection of biomarkers “inaccessible to other systems and at very low levels of detection.”
The companies are currently developing a cardiac point of care panel, as well as “other unique biomarker applications,” e2v Biosensors’ CEO, Paul Rodgers, said in a statement.
Rogers added that the company is seeking strategic partners to help commercialize the Visucare platform in “a broad range of point-of-care and pathology applications.”

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.